Español 
English
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody.
Artículos Relacionados
-
UDIBI
Fecha de publicación: Marzo 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio Ver más
-
UDIBI
Fecha de publicación: Enero 2019Valproic acid promotes a decrease in mycobacterial survival by enhancing nitric oxide production in macrophages...
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. VER MÁS
-
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. VER MÁS
0 Comentarios
